
June 2 (Reuters) - Kymera Therapeutics Inc KYMR.O:
KYMERA THERAPEUTICS ANNOUNCES POSITIVE FIRST-IN-HUMAN RESULTS FROM PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER
KYMERA THERAPEUTICS INC - KT-621 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS
KYMERA THERAPEUTICS INC - KT-621 PHASE 1B TRIAL DATA EXPECTED 4Q25
KYMERA THERAPEUTICS INC - PHASE 2B TRIALS IN AD AND ASTHMA TO START 4Q25 AND 1Q26